Certains contenus de cette application ne sont pas disponibles pour le moment.
Si cette situation persiste, veuillez nous contacter àObservations et contact
1. (WO2018227176) APPLICATION D'ANTICORPS ANTI-CD39L3 POUR UNE UTILISATION DANS LE DIAGNOSTIC ET L'IMAGERIE DE MALADIES
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

V. CLAIMS

What is claimed is:

1. A method of non-invasively detecting islet β-cell mass in a subject comprising

a) administering to the subject an anti-CD39L3 antibody; and

b) assaying for the anti-CD39L3 antibody.

2. A method of non-invasively detecting islet β-cell mass in a subject comprising

a) administering to the subject an anti-CD39L3 antibody; and

b) obtaining a pancreatic tissue sample from the subject

c) assaying for the anti-CD39L3 antibody.

3. The method of any of claims 1 or 2, wherein the administered anti-CD39L3 antibody is primary antibody conjugated to a detectable marker.

4. The method of any of claims 1-3, wherein the detectable marker is a fluorophore, biotin or a first morpholino.

5. The method of any of claims 1-4, wherein the method further comprises a secondary labeled antibody which is specific for conjugated marker on the primary antibody.

6. The method of any of claims 1-4, wherein the method further comprises a labeled complementary morpholino which is complementary to the first morpholino conjugated to the primary antibody.

7. A method of isolating islet β-cells from a tissue sample from a subject comprising contacting the tissue sample with an anti-CD39L3 antibody and separating the cells expressing CD39L3 using fluorescence activated cell sorting (FACS) or magnetic bead separation to detect cells bound by the CD39L3 antibody; wherein the cells expressing CD39L3 are islet β-cells.

8. A method of treating diabetes in a subject comprising

a) obtaining a pancreatic tissue sample from a donor;

b) contacting the pancreatic tissue sample with a labeled anti-CD39L3 antibody, wherein the anti-CD39L3 antibody binds to islet β-cells from the pancreatic tissue sample;

c) isolating the islet β-cells using magnetic beads or fluorescence activated cell sorting; and

d) transferring the isolated islet β-cells from the donor to the subject with diabetes.

9. A method of detecting diabetes in a subject comprising contacting the islet β-cells of the subject with an anti-CD39L3 antibody and measuring the mass of the islet β-cells; wherein a decrease in cell mass relative to a control indicates that a subject has diabetes.

10. The method of claim 9, wherein the islet β-cells are contacted with the CD39L3 antibody in vivo and the cell mass is assessed using one or more imaging method selected from bioluminescence (BLI), magnetic resonance imaging (MRI), Positron emission tomography (PET), Single photon emission computed tomography (SPECT), computed tomography (CT) scanning, and/or fluorescence molecular tomography (FMT).

11. The method of claim 9, wherein the islet β-cells are obtained from a tissue sample obtained from the subject and the islet β-cells are contacted with the anti-CD39L3 antibody ex vivo.

12. The method of claim 11 wherein the islet β-cell mass is assessed by an immunoassay selected from the group consisting of Radioimmunoassay (RIA), Enzyme-Linked

Immunosorbent Assay (ELISA), Enzyme-Linked Immuno spot Assay (ELISPOT), Flow cytometry, fluorescence activated cell sorting (FACS), protein array, multiplexed bead assay, and magnetic capture.

13. A method of testing the efficacy of an agent that is designed to increase islet β-cell mass comprising

a) administering the agent to a subject;

b) administering an anti-CD39L3 antibody to the subject, wherein the anti-CD39L3 antibody binds to β islet cells; and

c) measuring the β islet cell mass; wherein an increase in the β islet cell mass relative to a control indicates that the agent increases β islet cell mass.

14. A method of testing the efficacy of islet β-cell transplant comprising

a) administering an anti-CD39L3 antibody to the subject, wherein the anti-CD39L3 antibody binds to islet β-cells; and

b) detecting the labeled islet β-cells in the subject by imaging or immunoassay.